SCHEMBL3001231

SCHEMBL3001231

Cc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)cc4)cs3)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
LMNA P02545 3/20 0.42
GBA1 P04062 1/20 0.42
CHIT1 Q13231 2/20 0.38
CHIA Q9BZP6 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.36
DNM1L O00429 1/20 0.36
DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011260 1.00 MAPT (0.42) MAPTLMNAGBA1CHIT1CHIA
SCHEMBL3017469 0.95 GBA1 (0.45) MAPTLMNAGBA1SMN1; SMN2NPC1
SCHEMBL3017031 0.95 MAPT (0.42) MAPTLMNAGBA1SMN1; SMN2NPC1
SCHEMBL3018372 0.92 MAPT (0.39) MAPTLMNAGBA1SMN1; SMN2KMT2A
SCHEMBL3003648 0.92 SMN1; SMN2 (0.38) MAPTLMNAGBA1SMN1; SMN2NPC1
SCHEMBL3013097 0.92 GBA1 (0.42) MAPTLMNAGBA1SMN1; SMN2NPC1
SCHEMBL3020257 0.91 MAPT (0.38) MAPTLMNAGBA1SMN1; SMN2KMT2A
SCHEMBL3017967 0.91 GBA1 (0.42) MAPTLMNAGBA1SMN1; SMN2NPC1
SCHEMBL3016706 0.90 MAPT (0.37) MAPTLMNASMN1; SMN2KMT2ANPSR1
SCHEMBL3011786 0.90 MAPT (0.39) MAPTLMNASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885GBA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.